Publication | Closed Access

Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs

Schedule-dependent InhibitionLymphoid NeoplasiaMedicineImmunologyImmune Checkpoint InhibitorMtor Inhibitor EverolimusPharmacotherapyT-cell Lymphoma CellsAnti-cancer AgentImmunotherapyPharmacologyTumor MicroenvironmentDrug Discovery